The Clinicopathological Risk Factors in Renal Cell Cancer for the Oncological Outcomes Following Nephron-Sparing Surgery: A PRISMA Systematic Review and Meta-Analysis
Authors:
Open Access
- 6 March 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10, 286
Abstract
Background and Objectives: Published data from individual studies present conflicting evidence about the relationship between clinicopathological risk factors and oncological outcomes in renal cell cancer (RCC) following nephron-sparing surgery (NSS). This study was conducted to explore the potential risk factors for RCC progress after NSS. Methods: Studies published in PubMed, Web of Science, and EMBASE were systematically reviewed from inception to March 2019 to determine risk factors for RCC following NSS. The predictive ability of identified predictors was assessed by hazard ratios (HRs) with 95% confidence intervals (CIs). A fixed-effect or random-effect was used to pool the estimates. Subgroup analyses were performed to explore the source of heterogeneity. Results: Seventeen studies including 38,522 patients with RCC were analyzed. The meta-analysis indicated that positive surgical margin (pooled HR = 1.47; 95% CI:1.24–1.73; P < 0.001), higher Fuhrman grade (pooled HR = 1.58; 95% CI:1.10–2.28; P = 0.013), higher pathological stage (pooled HR = 1.72; 95% CI:1.40–2.12; P < 0.001) and large tumor size (pooled HR = 1.09; 95% CI:1.03–1.16; P = 0.003) were significantly associated with recurrence risk. However, age (pooled HR = 1.00; 95% CI: 1.00–1.01; P = 0.257), sex (male vs. female) (pooled HR = 1.04; 95% CI: 0.89–1.21; P = 0.605) and surgical approach (laparoscope vs. open) (pooled HR = 0.80; 95% CI: 0.59–1.07; P = 0.129) had no effect on recurrence after NSS. In addition, we found that positive surgical margin was significantly associated with recurrence-free survival (pooled HR = 1.87; 95% CI: 1.32–2.66; P < 0.001) and overall mortality (pooled HR = 1.15; 95% CI: 1.07–1.23; P < 0.001), as well as large tumor size for recurrence-free survival (pooled HR = 1.18; 95% CI: 1.06–1.30; P = 0.002)and overall mortality (pooled HR = 1.01; 95% CI: 1.00–1.02; P = 0.004). Conclusions: Unfavorable pathological characteristics were distinctly related to worse oncological outcomes in RCC patients following NSS. These results may contribute to proposed prediction models for RCC patients to aid in counseling and risk stratification.Keywords
This publication has 39 references indexed in Scilit:
- Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre seriesBJU International, 2011
- Kattan postoperative nomogram for renal cell carcinoma: Predictive accuracy in a Japanese populationInternational Journal of Urology, 2011
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- 7-Year Oncological Outcomes After Laparoscopic and Open Partial NephrectomyJournal of Urology, 2010
- Guideline for Management of the Clinical T1 Renal MassJournal of Urology, 2009
- The ‘Stage, Size, Grade and Necrosis’ score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer‐specific survival in patients with clear cell renal cell carcinomaBJU International, 2008
- Positive Surgical Margins at Partial Nephrectomy: Predictors and Oncological OutcomesJournal of Urology, 2008
- Surgical outcomes of partial nephrectomy for renal cell carcinoma: A joint study by the Japanese Society of Renal CancerInternational Journal of Urology, 2007
- Five‐year survival after surgical treatment for kidney cancerCancer, 2007
- External Validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) Score to Predict Cancer Specific Survival Using a European Series of Conventional Renal Cell CarcinomaJournal of Urology, 2006